Research and experimental development on natural sciences and engineering
SERCA PHARMACEUTICALS AS
Revenue 2024
NOK 4.7m
Operating profit
NOK −1.5m
Equity
NOK 27.6m
Incorporated
2018
Share capital
NOK 896,000
Roles
Daglig lederKjetil Hestdal
Regnskapsfører
Revisor
Styrets lederErlend Petter Skagseth
StyremedlemKristin Sandereid
StyremedlemJens Halvard Grønlien
Shareholders
| Name | Stake | Shares | Year |
|---|---|---|---|
| SARSIA SEED FOND II AS | 40.4% | 362247.000000 | 2025 |
| INVEN2 AS | 26.1% | 234032.000000 | 2025 |
| SATURN INVEST AS | 10.9% | 97632.000000 | 2025 |
| MP PENSJON PK | 9.1% | 81438.000000 | 2025 |
| HERSETH AS | 4.5% | 40000.000000 | 2025 |
| K OG K AS | 2.6% | 23385.000000 | 2025 |
| IFH CONSULTING AS | 2.5% | 22260.000000 | 2025 |
| KJETIL TASKEN | 0.8% | 7070.000000 | 2025 |
| KRISTIN SANDEREID | 0.6% | 5246.000000 | 2025 |
| TORBJØRN LEIV ØYE | 0.5% | 4880.000000 | 2025 |
| BIRGITTE LYGREN | 0.5% | 4200.000000 | 2025 |
| ELLEN ØSTENSEN | 0.4% | 3640.000000 | 2025 |
| ANA ISABEL COSTA CALEJO | 0.4% | 3540.000000 | 2025 |
| DRUG DISCOVERY LABORATORY AS | 0.3% | 2960.000000 | 2025 |
| IVAR SJAASTAD | 0.2% | 1740.000000 | 2025 |
| JAN MAGNUS ARONSEN | 0.1% | 1280.000000 | 2025 |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.